ClinicalTrials.gov
ClinicalTrials.gov Menu

Apnex Clinical Study of the Hypoglossal Nerve Stimulation (HGNS®) System to Treat Obstructive Sleep Apnea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01446601
Recruitment Status : Terminated
First Posted : October 5, 2011
Last Update Posted : April 15, 2015
Sponsor:
Information provided by (Responsible Party):
Apnex Medical, Inc.

Study Description
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the benefits and risks of hypoglossal nerve stimulation with the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System as a potential therapeutic option for individuals with moderate to severe Obstructive Sleep Apnea (OSA) that have failed or do not tolerate positive airway pressure (PAP) therapy.

Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Device: Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical ) Phase 3

Study Design
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pivotal Study of the Apnex Medical™ Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea
Study Start Date : August 2011
Actual Primary Completion Date : August 2013
Actual Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea
U.S. FDA Resources

Arms and Interventions
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Treatment
The Treatment Arm is implanted with the HGNS System and therapy is turned on at 1 month post-implant.
 Device: Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
Control
The Control Arm is implanted with the HGNS System and therapy is turned on at 7 months post-implant.
 Device: Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.


Outcome Measures
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Reduction in OSA Severity [ Time Frame: from Baseline to 6 Months ]
    The proportion of subjects that experience clinically meaningful improvement in AH1 (reduction >50% and AHI <20) and ODI 4% (reduction >= 25% or ODI 4% <5)from Baseline to 6 Months will be significantly greater in the Treatment Group compared to the Control Group

  2. Long-term Reduction in OSA Severity [ Time Frame: 12 months ]
    The proportion of subjects in the Treatment Group that experience clinically relevant improvement in AHI (reduction >50% and AHI <20) and ODI 4% (reduction >=25% or ODI 4% <5 at 12 months compared to Baseline.

  3. Safety Analysis [ Time Frame: 12 months ]
    Description of all adverse events


Eligibility Criteria
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 21 to 80 years
  • Body mass index (BMI) ≤ 35 kg/m²
  • Previously diagnosed with Moderate to severe OSA
  • Individual has failed or does not tolerate PAP therapy
Contacts and Locations
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01446601


Locations
United States, Kansas
MidAmerica Neuroscience Research Institute
Lenexa, Kansas, United States, 66214
Veritas Clinical Specialties
Topeka, Kansas, United States, 66606
United States, Kentucky
Kentucky Research Group
Louisville, Kentucky, United States, 40217
United States, Maryland
The Center for Sleep and Wake Disorders
Chevy Chase, Maryland, United States, 20815
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55454
United States, Missouri
St. Lukes Hospital
St. Louis, Missouri, United States, 63017
United States, New York
Clinilabs
New York, New York, United States, 10019
United States, North Carolina
Wilmington Medical Research
Wilmington, North Carolina, United States, 28401
United States, Ohio
Community Research
Cincinnati, Ohio, United States, 45230
United States, South Carolina
Sleep Med of South Carolina
Columbia, South Carolina, United States, 29201
United States, Texas
Sleep Therapy and Research Center
San Antonio, Texas, United States, 78229
Australia, New South Wales
Westmead Hospital
Sydney, New South Wales, Australia, 2145
Australia, Victoria
IBAS, The Austin Hospital
Melbourne, Victoria, Australia, 3084
Sponsors and Collaborators
Apnex Medical, Inc.
More Information
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Apnex Medical, Inc.
ClinicalTrials.gov Identifier: NCT01446601     History of Changes
Other Study ID Numbers: CLP-005
IDE #G090014 ( Other Identifier: FDA )
First Posted: October 5, 2011    Key Record Dates
Last Update Posted: April 15, 2015
Last Verified: December 2011

Keywords provided by Apnex Medical, Inc.:
Apnea
OSA
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
 Hypoglossal Nerve Stimulation
Sleep Disorders
Tongue

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
 Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases